Apimeds Pharmaceuticals US, Inc. (APUS)
APUS moved a median of -0.55% 30 minutes after news, and -1.16% by the close. How APUS actually reacts to news — the realized, point-in-time move the market made, measured across 113 labeled events over the last three years with zero look-ahead.
APUS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.55% | 23% | 86 |
| 30-min | -0.55% | 34% | 92 |
| 60-min | -0.54% | 37% | 94 |
| to close | -1.16% | 37% | 93 |
| Middle 50% of APUS reactions | -3.32% to +0.84% |
|---|---|
| Median reaction (30-min) | -0.55% |
| Measured reactions | 113 |
Half of all Apimeds Pharmaceuticals US, Inc. news events land between -3.32% and +0.84% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when APUS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to APUS's baseline. Nothing else.
Recent APUS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Apimeds Pharmaceuticals For: Oct 04 | SEC filing · Form 8-K | SEC EDGAR | -5.34% | -5.13% | |
| NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users Worldwide | Press release | GlobeNewswire | -0.11% | -1.28% | |
| MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure | Press release | GlobeNewswire | +3.22% | -4.24% | |
| MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network | Press release | GlobeNewswire | -14.63% | -8.02% | |
| Form 8-K Apimeds Pharmaceuticals For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +1.22% | -16.33% | |
| Form 8-K Apimeds Pharmaceuticals For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | -3.77% | -0.79% | |
| MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media | Press release | GlobeNewswire | -2.89% | -18.64% | |
| MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits | Press release | GlobeNewswire | +6.03% | -29.41% | |
| Form 8-K Apimeds Pharmaceuticals For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | +26.52% | |
| IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc. | Press release | GlobeNewswire | — | -3.54% | |
| Form 8-K Apimeds Pharmaceuticals For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | -2.55% | |
| Form 8-K Apimeds Pharmaceuticals For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.45% | |
| Form 10-Q Apimeds Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.35% | +24.06% | |
| Form 8-K Apimeds Pharmaceuticals For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | -10.57% | |
| NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange | Press release | GlobeNewswire | +0.00% | -6.37% | |
| MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October | Press release | GlobeNewswire | -6.53% | +20.12% | |
| Form 8-K Apimeds Pharmaceuticals For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +1.25% | +1.58% | |
| Form 10-Q Apimeds Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +6.34% | +0.00% | |
| Form NT 10-Q Apimeds Pharmaceuticals For: Mar 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | -1.32% | |
| Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lokahi Therapeutics to Advance Apitox Program | Press release | Business Wire | — | +30.43% | |
| Form 8-K Apimeds Pharmaceuticals For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +57.90% | |
| Form 10-K Apimeds Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| Form 8-K Apimeds Pharmaceuticals For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Apimeds Pharmaceuticals For: Apr 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Apimeds Pharmaceuticals For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K/A Apimeds Pharmaceuticals For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form NT 10-K Apimeds Pharmaceuticals For: Dec 31 | SEC filing · Form NT | SEC EDGAR | — | -2.23% | |
| Form 8-K Apimeds Pharmaceuticals For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | — | +17.90% | |
| Form 8-K Apimeds Pharmaceuticals For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.57% | |
| Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc. | Press release | GlobeNewswire | +0.00% | +0.57% | |
| Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery | Press release | Business Wire | -1.06% | -9.52% | |
| Form 8-K Apimeds Pharmaceuticals For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +3.85% | +3.11% | |
| Form DEFM14C Apimeds Pharmaceuticals | SEC filing · Form DEFM14C | SEC EDGAR | — | +2.26% | |
| Form 8-K/A Apimeds Pharmaceuticals For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | +1.23% | +4.10% | |
| Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox) | Press release | Business Wire | +6.20% | -19.71% | |
| Form PREM14C Apimeds Pharmaceuticals For: Jan 16 | SEC filing · Form PREM14C | SEC EDGAR | +0.00% | +2.44% | |
| Form 8-K Apimeds Pharmaceuticals For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | +4.19% | +10.78% | |
| E.F. Hutton Advises on Strategic Merger Between Apimeds and MindWave, Aligning Biotech Growth with AI-Enabled Financial Innovation | Press release | GlobeNewswire | — | -6.22% | |
| Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy | Press release | Business Wire | +1.36% | -4.98% | |
| Form 8-K Apimeds Pharmaceuticals For: Dec 05 | SEC filing · Form 8-K | SEC EDGAR | +2.29% | -3.67% | |
| Form 8-K/A Apimeds Pharmaceuticals For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | +2.29% | -3.67% | |
| Form 8-K Apimeds Pharmaceuticals For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | -2.74% | +0.46% | |
| Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE | Press release | Business Wire | -21.99% | -31.02% | |
| Form 8-K Apimeds Pharmaceuticals For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.66% | |
| Form 10-Q Apimeds Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.83% | — | |
| Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation | Press release | Business Wire | +3.83% | +11.92% | |
| Form 8-K Apimeds Pharmaceuticals For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +3.23% | -1.07% | |
| Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business | Press release | Business Wire | -7.18% | -7.69% | |
| Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development | Press release | Business Wire | +0.60% | +0.00% | |
| Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program | Press release | Business Wire | +0.00% | +5.05% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the APUS section they belong to.
Where else APUS is measured.
APUS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Apimeds Pharmaceuticals US, Inc.'s median reaction calculated?
Every labeled APUS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 113 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 34% of APUS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does APUS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.